The report is titled as ‘Antiplatelet Drugs Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the antiplatelet drugs market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market. Antiplatelet drugs market is expected to grow with significant rate in the near future.
The global antiplatelet drugs market in 2020 is estimated for more than US$ 1.7 Bn and expected to reach a value of US$ 2.4 Bn by 2028 with a significant CAGR of 7.6%.
Antiplatelet Drugs Market Definition
Antiplatelet drugs are endorsed to people with a background marked by heart attacks and these medications help in decreasing reoccurrence of heart attacks. A portion of the antiplatelet drugs incorporate, ibuprofen, clopidogrel, prasugrel, and ticagrelor. Aspirin is suggested for all patients with Acute Coronary Syndrome (ACS), in the absence of hypersensitivity. It is prescribed alongside one of the oral antiplatelet agents including Clopidogrel, Prasugrel, and Ticagrelor. Prasugrel is prescribed for patients experiencing ACS and for those experiencing Percutaneous Coronary Intervention (PCI). Clopidogrel and Ticagrelor help in anticipating atherothrombotic events in adult patients with ACS, and the individuals who are treated with Coronary Artery Bypass Grafting (CABG) or PCI.
Antiplatelet Drugs Market Dynamics
Increasing prevalence of cardiovascular issue, developing geriatric populace, and stationary way of life are a portion of the main considerations driving the global antiplatelet drugs market development. Cardiovascular diseases are the central reason for death in the developed and developing economies around the globe. As per a report by Centers for Disease Control and Prevention (CDC), 2015, around 800,000 individuals in the U.S. die yearly because of stroke and other cardiovascular diseases. A portion of the normal cardiovascular sicknesses incorporate, rheumatic coronary illness, hypertensive coronary illness, incendiary coronary illness, ischemic coronary illness, and cerebrovascular coronary illness.
Antiplatelet Drugs Market Segmentation
The antiplatelet drugs market is segmented on the basis of drug type, application, end user, and by region.
By Drug Type
• Aspirin
• Clopidogrel
• Ticagrelor
• Prasugrel
• Dipyridamole
• Ticlopidine
• Abciximab
• Tirofiban
• Others
By Application
• Myocardial Infraction
• Percutaneous Coronary Interventions
• Angioplasty
• Arterial Thrombosis
• Dental surgeries
• Others
By End User
• Hospitals
• Clinic
• Emergency Service Centers
• Ambulatory Surgical Centers
• Others
Antiplatelet Drugs Market Key Players
Some of the key participating players in antiplatelet drugs market are
• AstraZeneca Inc.
• The Medicines Company
• Portola Pharmaceuticals, Inc.
• Bayer Pharmaceuticals
• Bristol-Myers Squibb Company
• Boehringer Ingelheim Pharmaceuticals Inc.
• Altimed Pharma Inc.
• Dominion Pharmacal
• Alta Laboratories Ltd.
• Novacap
• Shandong Xinhua Pharmaceutical
• Nanjing Pharmaceutical Factory
• Sanis Health Inc.
• Syntex Inc.
• Hoffmann La Roche
• Teva Pharmaceutical
• Sandoz Canada Incorporated
• Pharmascience Inc.
• Nu Pharm Inc.
• Mylan Pharmaceuticals
Antiplatelet Drugs Market Regional Analysis and Overview
North America and Europe antiplatelet drugs market are relied upon to predict critical development by 2026 as cardiovascular sicknesses are the chief reason for death in these districts. As indicated by an European Heart Journal 2014 examination, Coronary Heart Diseases (CHD), especially Myocardial Infarction (MI), is in charge of around 1.8 million passings in Europe, every year.
Expanding pervasiveness of cardiovascular diseases in Asia Pacific is relied upon to fuel the antiplatelet market development in the region. As indicated by the American Heart Association, in 2011, 17,050 passings among Asian and Pacific Islanders were because of cardiovascular diseases; 7,828 because of coronary illness; and 2,476 because of myocardial localized necrosis.
In any case, as per the American Heart Journal 2015 database, individuals in Asia Pacific are susceptible to antithrombotics or fibrinolytics and to be related with a higher bleeding risk amid the board of ischemic heart diseases and antithrombotic therapy. For example, excessive bleeding risk with standard dosages of new P2Y12 inhibitors is seen in patients in Asia Pacific, particularly in its eastern region. As indicated by the Circulation Journal 2014 report, for Prasugrel, a lower maintenance dose of 3.75 mg day by day was utilized in clinical studies and approved for Japanese patients. The lower body load of patients in Asia Pacific, fixed dose routine of most antiplatelet drugs, and distinctive hereditary foundations are the potential variables in charge of expanded danger of dying. Thusly, bleeding is seen as an essential worry for choosing antiplatelet drugs for patients in Asia Pacific.
MMC Overview on Antiplatelet Drugs Market Report
The non-identical approach of Meridian Market Consultants stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give better opportunity for the customers to put their effort.
A research report on the Antiplatelet Drugs market by Meridian Market Consultants is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that supports market and the factors that are acting as impedance for the growth of the market.
Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.
Factors that are benchmarked while estimating the market
Various factors that are benchmarked while estimating the market growth includes (but not restricted to):
• New product designs and launches
• Current product compliance
• Reimbursement
• Concerns for use of Antiplatelet Drugs
• Advantages of Antiplatelet Drugs over other modalities
Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to take informed decision.
A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s product sales, previous growth rates and market expansion plans are considered to generate market share in the global market.
1. Global Antiplatelet Drugs Market Report Overview
1.1. Introduction
1.2. Report Description
1.3. Methodology
2. Global Antiplatelet Drugs Market Overview
2.1. Introduction
2.1.1. Market Definition
2.1.2. Market Taxonomy
2.2. Executive Summary
2.3. Global Antiplatelet Drugs Market Snapshot
2.4. Global Antiplatelet Drugs Market Size and Forecast, 2020–2028
2.4.1. Introduction
2.4.2. Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)
2.5. Global Antiplatelet Drugs Market Dynamics
2.5.1. Drivers
2.5.2. Restraints
2.5.3. Opportunity
2.5.4. Trends
2.6. Key Regulations
2.7. Porter’s Five Forces Model
3. Global Antiplatelet Drugs Market, By Drug Type
3.1. Introduction
3.1.1. Annual Growth Rate Comparison, By Drug Type
3.1.2. BPS Analysis, By Drug Type
3.2. Market Revenue (US$Mn) Forecast, By Drug Type
3.2.1. Aspirin
3.2.2. Clopidogrel
3.2.3. Ticagrelor
3.2.4. Prasugrel
3.2.5. Dipyridamole
3.2.6. Ticlopidine
3.2.7. Abciximab
3.2.8. Tirofiban
3.2.9. Others
3.3. Global Antiplatelet Drugs Market Attractiveness Index, By Drug Type
4. Global Antiplatelet Drugs Market, By Application
4.1. Introduction
4.1.1. Annual Growth Rate Comparison, By Application
4.1.2. BPS Analysis, By Application
4.2. Market Revenue (US$Mn) Forecast, By Application
4.2.1. Myocardial Infraction
4.2.2. Percutaneous Coronary Interventions
4.2.3. Angioplasty
4.2.4. Arterial Thrombosis
4.2.5. Dental surgeries
4.2.6. Others
4.3. Global Antiplatelet Drugs Market Attractiveness Index, By Application
5. Global Antiplatelet Drugs Market, By End User
5.1. Introduction
5.1.1. Annual Growth Rate Comparison, By End User
5.1.2. BPS Analysis, By End User
5.2. Market Revenue (US$Mn) Forecast, By End User
5.2.1. Hospitals
5.2.2. Clinic
5.2.3. Emergency Service Centers
5.2.4. Ambulatory Surgical Centers
5.2.5. Others
5.3. Global Antiplatelet Drugs Market Attractiveness Index, By End User
6. Global Antiplatelet Drugs Market, By Region
6.1. Introduction
6.1.1. Annual Growth Rate Comparison, By Region
6.1.2. BPS Analysis, By Region
6.2. Market Revenue (US$Mn) Forecast, By Region
6.2.1. North America
6.2.2. Latin America
6.2.3. Europe
6.2.4. Asia Pacific
6.2.5. Middle East
6.2.6. Africa
6.3. Global Antiplatelet Drugs Market Attractiveness Index, By Region
7. North America Antiplatelet Drugs Market Analysis and Forecast, 2020–2028
7.1. Introduction
7.1.1. Annual Growth Rate Comparison, By Country
7.1.2. BPS Analysis, By Country
7.2. Market Revenue (US$Mn) Forecast, By Country
7.2.1. U.S. Antiplatelet Drugs Market
7.2.2. Canada Antiplatelet Drugs Market
7.3. North America Antiplatelet Drugs Market, By Drug Type
7.3.1. Aspirin
7.3.2. Clopidogrel
7.3.3. Ticagrelor
7.3.4. Prasugrel
7.3.5. Dipyridamole
7.3.6. Ticlopidine
7.3.7. Abciximab
7.3.8. Tirofiban
7.3.9. Others
7.4. North America Antiplatelet Drugs Market, By Application
7.4.1. Myocardial Infraction
7.4.2. Percutaneous Coronary Interventions
7.4.3. Angioplasty
7.4.4. Arterial Thrombosis
7.4.5. Dental surgeries
7.4.6. Others
7.5. North America Antiplatelet Drugs Market, By End User
7.5.1. Hospitals
7.5.2. Clinic
7.5.3. Emergency Service Centers
7.5.4. Ambulatory Surgical Centers
7.5.5. Others
7.6. North America Antiplatelet Drugs Market Attractiveness Index
7.6.1. By Country
7.6.2. By Drug Type
7.6.3. By Application
7.6.4. By End User
8. Latin America Antiplatelet Drugs Market Analysis and Forecast, 2020–2028
8.1. Introduction
8.1.1. Annual Growth Rate Comparison, By Country
8.1.2. BPS Analysis, By Country
8.2. Market (US$Mn) Forecast, By Country
8.2.1. Brazil Antiplatelet Drugs Market
8.2.2. Mexico Antiplatelet Drugs Market
8.2.3. Argentina Antiplatelet Drugs Market
8.2.4. Rest of Latin America Antiplatelet Drugs Market
8.3. Latin America Antiplatelet Drugs Market, By Drug Type
8.3.1. Aspirin
8.3.2. Clopidogrel
8.3.3. Ticagrelor
8.3.4. Prasugrel
8.3.5. Dipyridamole
8.3.6. Ticlopidine
8.3.7. Abciximab
8.3.8. Tirofiban
8.3.9. Others
8.4. Latin America Antiplatelet Drugs Market, By Application
8.4.1. Myocardial Infraction
8.4.2. Percutaneous Coronary Interventions
8.4.3. Angioplasty
8.4.4. Arterial Thrombosis
8.4.5. Dental surgeries
8.4.6. Others
8.5. Latin America Antiplatelet Drugs Market, By End User
8.5.1. Hospitals
8.5.2. Clinic
8.5.3. Emergency Service Centers
8.5.4. Ambulatory Surgical Centers
8.5.5. Others
8.6. Latin America Antiplatelet Drugs Market Attractiveness Index
8.6.1. By Country
8.6.2. By Drug Type
8.6.3. By Application
8.6.4. By End User
9. Europe Antiplatelet Drugs Market Analysis and Forecast, 2020–2028
9.1. Introduction
9.1.1. Annual Growth Rate Comparison, By Country
9.1.2. BPS Analysis, By Country
9.2. Market (US$Mn) Forecast, By Country
9.2.1. U.K. Antiplatelet Drugs Market
9.2.2. Germany Antiplatelet Drugs Market
9.2.3. Italy Antiplatelet Drugs Market
9.2.4. France Antiplatelet Drugs Market
9.2.5. Spain Antiplatelet Drugs Market
9.2.6. Russia Antiplatelet Drugs Market
9.2.7. Poland Antiplatelet Drugs Market
9.2.8. BENELUX Antiplatelet Drugs Market
9.2.9. NORDIC Antiplatelet Drugs Market
9.2.10. Rest of Europe Antiplatelet Drugs Market
9.3. Europe Antiplatelet Drugs Market, By Drug Type
9.3.1. Aspirin
9.3.2. Clopidogrel
9.3.3. Ticagrelor
9.3.4. Prasugrel
9.3.5. Dipyridamole
9.3.6. Ticlopidine
9.3.7. Abciximab
9.3.8. Tirofiban
9.3.9. Others
9.4. Europe Antiplatelet Drugs Market, By Application
9.4.1. Myocardial Infraction
9.4.2. Percutaneous Coronary Interventions
9.4.3. Angioplasty
9.4.4. Arterial Thrombosis
9.4.5. Dental surgeries
9.4.6. Others
9.5. Europe Antiplatelet Drugs Market, By End User
9.5.1. Hospitals
9.5.2. Clinic
9.5.3. Emergency Service Centers
9.5.4. Ambulatory Surgical Centers
9.5.5. Others
9.6. Europe Antiplatelet Drugs Market Attractiveness Index
9.6.1. By Country
9.6.2. By Drug Type
9.6.3. By Application
9.6.4. By End User
10. Asia Pacific Antiplatelet Drugs Market Analysis and Forecast, 2020–2028
10.1. Introduction
10.1.1. Annual Growth Rate Comparison, By Country
10.1.2. BPS Analysis, By Country
10.2. Market (US$Mn) Forecast, By Country
10.2.1. China Antiplatelet Drugs Market
10.2.2. India Antiplatelet Drugs Market
10.2.3. Japan Antiplatelet Drugs Market
10.2.4. Australia and New Zealand Antiplatelet Drugs Market
10.2.5. South Korea Antiplatelet Drugs Market
10.2.6. ASEAN Antiplatelet Drugs Market
10.2.7. Rest of Asia Pacific Antiplatelet Drugs Market
10.3. Asia Pacific Antiplatelet Drugs Market, By Drug Type
10.3.1. Aspirin
10.3.2. Clopidogrel
10.3.3. Ticagrelor
10.3.4. Prasugrel
10.3.5. Dipyridamole
10.3.6. Ticlopidine
10.3.7. Abciximab
10.3.8. Tirofiban
10.3.9. Others
10.4. Asia Pacific Antiplatelet Drugs Market, By Application
10.4.1. Myocardial Infraction
10.4.2. Percutaneous Coronary Interventions
10.4.3. Angioplasty
10.4.4. Arterial Thrombosis
10.4.5. Dental surgeries
10.4.6. Others
10.5. Asia Pacific Antiplatelet Drugs Market, By End User
10.5.1. Hospitals
10.5.2. Clinic
10.5.3. Emergency Service Centers
10.5.4. Ambulatory Surgical Centers
10.5.5. Others
10.6. Asia Pacific Antiplatelet Drugs Market Attractiveness Index
10.6.1. By Country
10.6.2. By Drug Type
10.6.3. By Application
10.6.4. By End User
11. Middle East Antiplatelet Drugs Market, By Region
11.1. Introduction
11.1.1. Annual Growth Rate Comparison, By Country
11.1.2. BPS Analysis, By Country
11.2. Market (US$Mn) Forecast, By Country
11.2.1. GCC Countries Antiplatelet Drugs Market
11.2.2. Israel Antiplatelet Drugs Market
11.2.3. Oman Antiplatelet Drugs Market
11.2.4. Rest of Middle East Antiplatelet Drugs Market
11.3. Middle East Antiplatelet Drugs Market, By Drug Type
11.3.1. Aspirin
11.3.2. Clopidogrel
11.3.3. Ticagrelor
11.3.4. Prasugrel
11.3.5. Dipyridamole
11.3.6. Ticlopidine
11.3.7. Abciximab
11.3.8. Tirofiban
11.3.9. Others
11.4. Middle East Antiplatelet Drugs Market, By Application
11.4.1. Myocardial Infraction
11.4.2. Percutaneous Coronary Interventions
11.4.3. Angioplasty
11.4.4. Arterial Thrombosis
11.4.5. Dental surgeries
11.4.6. Others
11.5. Middle East Antiplatelet Drugs Market, By End User
11.5.1. Hospitals
11.5.2. Clinic
11.5.3. Emergency Service Centers
11.5.4. Ambulatory Surgical Centers
11.5.5. Others
11.6. Middle East Antiplatelet Drugs Market Attractiveness Index
11.6.1. By Country
11.6.2. By Drug Type
11.6.3. By Application
11.6.4. By End User
12. Africa Antiplatelet Drugs Market, By Region
12.1. Introduction
12.1.1. Annual Growth Rate Comparison, By Country
12.1.2. BPS Analysis, By Country
12.2. Market (US$Mn) Forecast, By Country
12.2.1. South Africa Antiplatelet Drugs Market
12.2.2. Egypt Antiplatelet Drugs Market
12.2.3. North Africa Antiplatelet Drugs Market
12.2.4. Rest of Africa Antiplatelet Drugs Market
12.3. Africa Antiplatelet Drugs Market, By Drug Type
12.3.1. Aspirin
12.3.2. Clopidogrel
12.3.3. Ticagrelor
12.3.4. Prasugrel
12.3.5. Dipyridamole
12.3.6. Ticlopidine
12.3.7. Abciximab
12.3.8. Tirofiban
12.3.9. Others
12.4. Africa Antiplatelet Drugs Market, By Application
12.4.1. Myocardial Infraction
12.4.2. Percutaneous Coronary Interventions
12.4.3. Angioplasty
12.4.4. Arterial Thrombosis
12.4.5. Dental surgeries
12.4.6. Others
12.5. Africa Antiplatelet Drugs Market, By End User
12.5.1. Hospitals
12.5.2. Clinic
12.5.3. Emergency Service Centers
12.5.4. Ambulatory Surgical Centers
12.5.5. Others
12.6. Africa Antiplatelet Drugs Market Attractiveness Index
12.6.1. By Country
12.6.2. By Drug Type
12.6.3. By Application
12.6.4. By End User
13. Recommendation
13.1. Market Strategy
14. Competitive Landscape
14.1. Competition Dashboard
14.2. List and Company Overview of Global Key Players
14.3. Company Profiles
14.3.1. AstraZeneca PLC
14.3.1.1. Company Overview
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. Key Developments
14.3.1.5. Business Strategies
14.3.2. The Medicines Company
14.3.3. Portola Pharmaceuticals, Inc.
14.3.4. Bayer Pharmaceuticals
14.3.5. Bristol-Myers Squibb Company
14.3.6. Boehringer Ingelheim Pharmaceuticals Inc.
14.3.7. Altimed Pharma Inc.
14.3.8. Dominion Pharmacal
14.3.9. Alta Laboratories Ltd.
14.3.10. Novacap
14.3.11. Shandong Xinhua Pharmaceutical
14.3.12. Nanjing Pharmaceutical Factory
14.3.13. Sanis Health Inc
14.3.14. Syntex Inc.
14.3.15. Hoffmann La Roche
14.3.16. Teva Pharmaceutical
14.3.17. Sandoz Canada Incorporated
14.3.18. Pharmascience Inc.
14.3.19. Nu Pharm Inc.
14.3.20. Mylan Pharmaceuticals
15. Acronyms
Frequently Asked Questions
What is the projected market size & Compound Annual Growth Rate (CAGR) of the market?
The global antiplatelet drugs market in 2020 is estimated for more than US$ 1.7 Bn and expected to reach a value of US$ 2.4 Bn by 2028 with a significant CAGR of 7.6%.
What are the key factors driving the growth of market?
Increasing prevalence of cardiovascular issue, developing geriatric populace, and stationary way of life are a portion of the main considerations driving the global antiplatelet drugs market development.
What segments are covered in market report?
The antiplatelet drugs market is segmented on the basis of drug type, application, end user, and by region.
What are the key participating players in the market?
Some of the key participating players in antiplatelet drugs market are AstraZeneca Inc., The Medicines Company, Portola Pharmaceuticals, Inc., Bayer Pharmaceuticals, Bristol-Myers Squibb Company, Boehringer Ingelheim Pharmaceuticals Inc., Altimed Pharma Inc., Dominion Pharmacal, Alta Laboratories Ltd., Novacap, Shandong Xinhua Pharmaceutical, Nanjing Pharmaceutical Factory, Sanis Health Inc., Syntex Inc., Hoffmann La Roche, Teva Pharmaceutical, Sandoz Canada Incorporated, Pharmascience Inc., Nu Pharm Inc., and Mylan Pharmaceuticals
